(±)-2-Propyl-4-pentenoic acid
Based on 1 Customer Validation
(±)-2-Propyl-4-pentenoic acid (4-en-VPA) is a major toxic metabolite of Valproic acid. (±)-2-Propyl-4-pentenoic acid exhibits neuroteratogenicity.
For research use only. We do not sell to patients.
- Purity: 98.0%
- CAS No.: 1575-72-0
- Formula: C8H14O2
- Molecular Weight:142.20
-
Storage:Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
HY-124087R
(±)-2-Propyl-4-pentenoic acid (Standard)
-
HY-132242
DL-Sulforaphane N-acetyl-L-cysteine
-
HY-G0007
Omeprazole sulfone
-
HY-126848
Diclofenac acyl glucuronide
-
HY-W009247
N-Desmethylolanzapine
-
HY-113239
Hydroxycotinine
-
HY-118774
Propofol β-D-glucuronide
-
HY-114976
S-Allylmercapturic acid
-
HY-113093S
Ethyl glucuronide-d5
-
HY-131527R
Wy-45494 hydrochloride (Standard)
-
HY-Z4483
6-Deoxypenciclovir
-
HY-G0016
N-Acetyl dapsone
Biological Activity
(±)-2-Propyl-4-pentenoic acid (1 mM; 26 h) induces approximately 50% of dysmorphogenic mouse embryos[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1575-72-0
-
Appearance Liquid (Density: 0.943±0.06 g/cm3)
-
Molecular Weight 142.20
-
Formula C8H14O2
-
Color Colorless to light yellow
-
SMILES
C=CCC(CCC)C(O)=O
-
Synonyms
4-en-VPA; 2-Allylpentanoic acid
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Pure form -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 100 mg/mL (703.23 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (17.58 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (17.58 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (271 KB)
-
SDS (555 KB)
- English - EN (555 KB)
- Français - FR (555 KB)
- Deutsch - DE (555 KB)
- Norwegian - NO (555 KB)
- Español - ES (555 KB)
- Swedish - SV (555 KB)
- Italian - IT (555 KB)
- Korean - KR (555 KB)
- Portuguese - PT (555 KB)
-
Handling Instructions (2659 KB)
References
[1]. W Tang, et, al. A comparative investigation of 2-propyl-4-pentenoic acid (4-ene VPA) and its alpha-fluorinated analogue: phase II metabolism and pharmacokinetics. Drug Metab Dispos. 1997 Feb;25(2):219-27. [Content Brief]
[2]. Gofflot F, et, al. In vitro neuroteratogenicity of valproic acid and 4-en-VPA. Neurotoxicol Teratol. Jul-Aug 1995;17(4):425-35. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 7.0323 mL | 35.1617 mL | 70.3235 mL | 175.8087 mL |
| 5 mM | 1.4065 mL | 7.0323 mL | 14.0647 mL | 35.1617 mL | |
| 10 mM | 0.7032 mL | 3.5162 mL | 7.0323 mL | 17.5809 mL | |
| 15 mM | 0.4688 mL | 2.3441 mL | 4.6882 mL | 11.7206 mL | |
| 20 mM | 0.3516 mL | 1.7581 mL | 3.5162 mL | 8.7904 mL | |
| 25 mM | 0.2813 mL | 1.4065 mL | 2.8129 mL | 7.0323 mL | |
| 30 mM | 0.2344 mL | 1.1721 mL | 2.3441 mL | 5.8603 mL | |
| 40 mM | 0.1758 mL | 0.8790 mL | 1.7581 mL | 4.3952 mL | |
| 50 mM | 0.1406 mL | 0.7032 mL | 1.4065 mL | 3.5162 mL | |
| 60 mM | 0.1172 mL | 0.5860 mL | 1.1721 mL | 2.9301 mL | |
| 80 mM | 0.0879 mL | 0.4395 mL | 0.8790 mL | 2.1976 mL | |
| 100 mM | 0.0703 mL | 0.3516 mL | 0.7032 mL | 1.7581 mL |
(±)-2-Propyl-4-pentenoic acid Related Classifications
HY-124087 Related Classifications
Powered by Bioz